OOIR: Observatory of International Research

Papers

(The TQCC of Nature Reviews Neurology is 12. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-01-01 to 2026-01-01.)

Article	Citations
Transmembrane protein interacts with α-synuclein to confer risk of PD	596
Lymphatic propagation of α-synuclein	375
Promising results for antisense RNA therapy in mouse models of diffuse midline glioma	365
Brain stimulation aids walking after spinal injury	338
Ventricular enlargement caused by aducanumab	282
ANA2025 marks important milestones for the ANA and NINDS	269
Reply to ‘Perils and pitfalls of near-death experience research’	260
Epstein–Barr virus as a leading cause of multiple sclerosis: mechanisms and implications	258
Neural cell state shifts and fate loss in ageing and age-related diseases	252
Global synergistic actions to improve brain health for human development	244
Deciphering nociplastic pain: clinical features, risk factors and potential mechanisms	238
CD11c+ macrophages mediate brain-to-gut α-synuclein trafficking	235
Disease-specific modifications of tau protein	229
Continuous levodopa production by an artificial enzyme	224
TREM2 mediates phagocytosis in glioblastoma	222
Study reveals new ALS risk genes	177
SEQUINS — a new initiative to address disparities in neurology	175
Nir Giladi (1955–2024)	165
Spinal muscular atrophy treatment in utero	163
Rapidly progressive dementias — leukodystrophies as a potentially treatable cause	151
Mitochondrial DNA instability in Huntington disease	147
The role of the gut microbiota in multiple sclerosis	144
The impact of rare genetic variants on Alzheimer disease	143
The Digitized Memory Clinic	122
Imperatives and co-benefits of research into climate change and neurological disease	120

Psychosis-causing lesions mapped to a hippocampal circuit	119
Neuroinflammation predicts cognitive decline in FTD	113
Ultrasound lets gene therapy into the brain	111
Menopause influences tau pathology	111
Implications of AD plasma and PET biomarker discordance	111
Amyloid plaques: hotspots for microglial turnover	110
Brain volume is associated with cognition in MS	110
Challenges of combining multimodal data in assessment of people with traumatic brain injury	106
MRI-based deep learning for TLE diagnosis	105
Gene therapy for seizures in focal cortical dysplasia	102
Neurological care for LGBT+ people	94
Parkinson disease pathology can originate in the kidney	94
Author Correction: Viral pathogens increase risk of neurodegenerative disease	92
Precision neuroimmunology in multiple sclerosis — the horizon is near	91
First trials test targeting of α-synuclein for Parkinson disease	91
Implementation of the 2024 revision of the McDonald criteria for multiple sclerosis	90
The challenges of anti-tau therapeutics in Alzheimer disease	85
Management of freezing of gait — mechanism-based practical recommendations	84
α-Synuclein pathology as a target in neurodegenerative diseases	80
Diversity, equity and inclusion in neurology	80
The noradrenergic subtype of Parkinson disease: from animal models to clinical practice	79
Food is brain medicine — relevance and translation to neurology	76
Blood GFAP as an emerging biomarker in brain and spinal cord disorders	76
Neurosteroids alleviate seizures in rats	74
Glymphatic dysfunction in PD clinical progression	72
A new biological classification for Parkinson disease	69
Addressing disparities in neurology by building the workforce in LMICs	67
Ultrasound ablation treatment for PD	65
Thalamic inflammation — a therapeutic target for brain injury?	63
New IDEAS about amyloid, race and dementia disparities	62
Author Correction: Why won’t it stop? The dynamics of benzodiazepine resistance in status epilepticus	62
Coeliac disease as a model for understanding multiple sclerosis	62
From the prodromal stage of multiple sclerosis to disease prevention	61
Post-COVID dysautonomias: what we know and (mainly) what we don’t know	61
Knowing the enemy: strategic targeting of complement to treat Alzheimer disease	61
Why won’t it stop? The dynamics of benzodiazepine resistance in status epilepticus	61
Amyloid-lowering immunotherapies for Alzheimer disease: current status and future directions	59
Spinal cord stimulation for the treatment of chronic pain	57
The role of glial cells in multiple sclerosis disease progression	55
The global and regional burden of diabetic peripheral neuropathy	52
Is Alzheimer disease a disease?	51
Synaptic degeneration in Alzheimer disease	51
X-chromosome variants and PD in Latin America	48
Oligomeric tau could spread through synapses in AD	48
Hypothyroidism is associated with dementia risk	48
Genetic susceptibility determines Epstein–Barr-virus-associated risk of multiple sclerosis	47
Continuing evolution of migraine-specific therapies — targeting migraine with precision and persistence	47
Neurology in 2025 — reflections from Africa	46
Limbic-predominant age-related TDP43 encephalopathy (LATE) neuropathological change in neurodegenerative diseases	46
Neurofilament light chain induces neuroinflammation	46

The inter-relationship between delirium and dementia: the importance of delirium prevention	46
Global epidemiology of migraine and its implications for public health and health policy	46
Peripheral nervous system immune-related adverse events due to checkpoint inhibition	46
Dual function of biomolecular condensates	45
Moving towards meaningful patient and public engagement	45
Risk locus for paediatric astrocytoma identified	45
T cells implicate Epstein–Barr virus in multiple sclerosis pathogenesis	44
α-Synuclein seeds in amyotrophic lateral sclerosis	44
Prognostic plasma biomarkers for spinal cord injury	43
Multi-ancestry GWAS identifies 16 novel Alzheimer disease risk loci	43
Impaired glymphatic drainage links amyloid and tau to cognitive dysfunction	41
Reactive astrocyte biomarkers mirror Alzheimer disease pathology	40
Insights from 25 years of onabotulinumtoxinA in migraine — mechanisms and management	40
The role of astrocytic α7 nicotinic acetylcholine receptors in Alzheimer disease	40
Neurology in 2025 — reflections from the USA	40
Plasma extracellular vesicle biomarkers for frontotemporal dementia and related disorders	37
CAR T cells offer hope in glioblastoma	37
Huntington disease-like 2: insight into neurodegeneration from an African disease	35
The Miami Framework for ALS and related neurodegenerative disorders: an integrated view of phenotype and biology	35
New developments in guidelines for brain death/death by neurological criteria	35
Facioscapulohumeral muscular dystrophy: the road to targeted therapies	35
Inflammasomes in neurological disorders — mechanisms and therapeutic potential	32
Twin study probes non-heritable immune aspects of multiple sclerosis	31
Origins and immunopathogenesis of autoimmune central nervous system disorders	31
John Q. Trojanowski	30
Serum NfL as an MS biomarker	30
ALS pathogenesis linked to actin barrier collapse	28
Aberrant protein networks in Alzheimer disease	28
Pathogenetic mechanisms and treatment targets in cerebral malaria	27
AI aces diagnosis of chronic ataxias	27
BCAS1+ oligodendrocytes aid remyelination in MS	27
Genome-wide analysis furthers decoding of Alzheimer disease genetics	26
Pharmacological rehabilitation for stroke	26
Antisense oligonucleotide shows potential in Charcot–Marie–Tooth disease	26
Charting brain development across the human lifespan	25
The murky waters of sex differences in post-stroke cognitive impairment	25
Addressing disparities in the global epidemiology of stroke	24
AI and protein structure and function in neurological disease: relevance to disease management	24
Author Correction: The complex aetiology of cerebral palsy	24
Neuroprognostication: a conceptual framework	23
Molecular biomarkers for vascular cognitive impairment and dementia	22
Clocking the age of Parkinson disease onset	21
Nusinersen treatment response markers	20
Effects of diet on MS onset and course	20
Nanoprobe for blood–brain barrier changes	19
Altered muscle cholesterol transport in ALS	19
Predictive tools in psychosis: what is ‘good enough’?	18
Advancing multiple sclerosis management in older adults	18
Addressing racial inequities in neuropsychological assessment requires international prescriptive standards, not demographically adjusted norms	18
Disease-modifying therapies for Parkinson disease: lessons from multiple sclerosis	16
Alzheimer disease seen through the lens of sex and gender	16
Sex and gender in neurodevelopmental conditions	15
Markers help to predict dementia with Lewy bodies	15
From adaptive deep brain stimulation to adaptive circuit targeting	15
Mechanistic insights into the interaction between epilepsy and sleep	15
Multidimensional MRI detects astrogliosis	14
Shared glial pathology in HD and schizophrenia	14
Advances in the therapeutic algorithm for myasthenia gravis	13
Evidence-based clinical care and policy making for schizophrenia	13
Walking the Talk for Dementia — an experience to break down barriers	13
Timing of hormone replacement therapy could influence Alzheimer disease risk	13
Parkinson disease pathology in inflammatory bowel disease	13
Limitations of neurocentric models for near-death experiences	13
Author Correction: Why functional neurological disorder is not feigning or malingering	12
Inclusion in neurological research: empowering people living with neurological diseases	12
Seizure-associated changes in the Golgi apparatus	12
Alzheimer disease in Down syndrome linked to APOE	12
Multisite chronic pain: a risk factor for dementia	12